Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
CAPA 2015 Annual Conference
1
Common InheritedBleeding Disorders
Bob Miller, PA
October 8, 2015
VWF has two jobsLoosely bound to protect FVIII
and tether to site of injury
vWF+VIII
P
P
P
P
P
P
P
P PP
PvWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
All other coagulation factors also in circulation
Injury to the blood vessel
vWF+VIII
P
P
P
P
P
P
P
P PP
PvWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
Contact with tissue factor
and other subendothelial tissues
CAPA 2015 Annual Conference
2
Bleeding at site of injury with exposure tosubendothelium with platelet activation
vWF+VIII
P
P
P
P
P
P
P PP
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
VIII
vWF+VIII
P P
P
VWF “tethers” to exposed endotheliumat site of injury
vWF+VIII
P
P
P
P
P
P
P PP
VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
VIII
vWF+VIII
vWF vWF
Shear
vWF
pP
Platelets are activated and “adhere” to VWFand then “aggregate” to form “platelet plug”
vWF+VIII
P
P
P
P
P
P
P PP
VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
VIII
vWF+VIII
vWF vFW vWFP P
P
P
PP
CAPA 2015 Annual Conference
3
Activated coagulation proteins formfibrin strands
vWF+VIII
P
P
P
P
P
P
P PP
X
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF+VIII
vWF vWF vWFP
PP
P
P
P
IXXIIIVII
V
III
VIII
Fibrin Strands
Fibrin Clot
CAPA 2015 Annual Conference
4
Reproduced with permission from:Rao AK. Am J Med Sci.1998;316:69–76.
A representationof normal plateletresponses and thecongenitaldisorders ofplatelet function
Bernard SoulierSyndrome
vWD Glanzmann’sThrombasthenia
Deficiency of PlateletCoagulant Activities
Fibrinogen
GPIIb/III
a
Afibrinogenemia
CAPA 2015 Annual Conference
5
Copyright © 2011 American Society of Hematology. Copyright restrictions may apply.
Peter Maslak, ASH Image Bank 2011; 2011-3689
Petechiae
Patterns of Bleeding
Platelet type …
• mucous membrane
• epistaxis
• petechiae
• menorrhagia
Coagulation type ...
• bruising
• soft tissue
• muscles
• joints
Platelet Function Evaluation
• IVY bleeding time
• Plt Aggregation to : ADP
Epinephrine
Collagen
Ristocetin
Arachidonic acid
• PFA - Platelet function analyzer
CAPA 2015 Annual Conference
6
Inherited Disorders AffectingPlatelets
• Low von Willebrand factor protein (common)
von Willebrands Disease (VWD)
• Function defects in the platelet (rare)
Glannsman’s thrombasthenia
Bernard-Soulier syndrome
• Vessel wall abnormalities (rare)
Connective tissue disorders
Reproduced with permission from:Rao AK. Am J Med Sci.1998;316:69–76.
A representationof normal plateletresponses and thecongenitaldisorders ofplatelet function
Bernard SoulierSyndrome
vWD Glanzmann’sThrombasthenia
Deficiency of PlateletCoagulant Activities
Fibrinogen
GPIIb/III
a
Afibrinogenemia
VWD….bleeding
VWD
• Mucous membranes
• Epistaxis
• Menorrhagia
• Superficial (petechiae)
Hemophilia
• Deep bruising
• Joints
• Muscles
CAPA 2015 Annual Conference
7
von Willebrand Disease
• Estimated 1% of population (autosomal)
• Type 1 mild / most common
• Type 2 mild to moderate
• Type 3 severe
von Willebrand Disease
Type 1
• Reduced quantity of VWF
• VWF normal, just reduced
• Mild and most common
• ~ 80% of all VWD
VWD….diagnosis
FVIII
VWF:Ag
RCof
Type 1
All three partiallydecreased tosimilar levels
CAPA 2015 Annual Conference
8
Basic Bleeding Work-up
CBC w/ platelet ct NL
PT 11.2 (10-12)
PTT 46 (31-43)
Extra coag tube
FVIII 38 (50-150)
VWF Antigen 42 (50-150)
Ristocetin (R cof.) 35 (50-150)
Basic Bleeding Work-up
CBC w/ platelet ct NL
PT 10.9 (10-12)
PTT 46 (31-43)
Extra coag tube
FVIII 32 (50-150)
VWF Antigen 12 (50-150)
Ristocetin (R cof.) 0 (50-150)
von Willebrand Disease
Type 2
Qualitative defects in function
• Type 2A
Lacks HMW multimers
• Type 2B
“Gain of function”
Increased platelet binding = low plt ct
CAPA 2015 Annual Conference
9
von Willebrand Disease
Type 2
Qualitative defects in function
• Type 2M
Decreased binding to GP1
• Type 2N (Normandy)
Normal amount of VWF
(Ag & Rcof normal)
Decreased binding to FVIII = low FVIII
? Misdiagnosed as hemophilia A
A Short Case # 1
• MR is a 10 y/o Caucasian male scheduledfor a tonsillectomy
• HX of excess bleeding beginning severalhours after recent tooth extraction. Epistaxishas been rare and of short duration. Someminor bruising in the past – usually aftersports. No recent medications.
Case #1 Initial Lab Values
Pre-op lab values revealed:
• Prolonged PTT = 45 sec (24-38)
• Normal PT = 11.5 sec (10-13)
• CBC normal except for a plt ct of 95,000
CAPA 2015 Annual Conference
10
Case #1 Lab Workup
• Prolonged PTT ?
Factor VIII level = 36% (50-150)
• Low platelet ct ? VWD type 2B ?
VWF Ag = 38% (50-150)
Rcof = 11% (50-150)
• Further confirming workup
RIPA increased
Multimers = loss of HMW
VWF Multimers
von Willebrand Disease
Type 3
• VWF very low or absent
• Severe clinical features
CAPA 2015 Annual Conference
11
Basic Bleeding Work-up
CBC w/ platelet ct NL
PT 11.0 (10-12)
PTT, 1:1 mix 59 (31-43)
Extra coag tube
FVIII 3 (50-150)
VWF Antigen <12 (50-150)
Ristocetin R cof. <6 (50-150)
VWD ... lab tests
• VIII
• VWF:Ag
• RCof
• Bleeding time
• VWF multimers
• Blood group
• RIPA
• Platelet count
von Willebrand Disease
Diagnosis
• Repeated testing may be needed
• Bleeding history important
• Family history / inheritance
• Autosomal dominant / recessive
CAPA 2015 Annual Conference
12
Basic Bleeding Work-up
CBC w/ platelet ct NL
PT 11.1 (10-12)
PTT 43 (31-43)
Extra coag tube
FVIII c 60 (50-150)
VWF Antigen 41 (50-150)
Ristocetin (R cof.) 52 (50-150)
von Willebrand Disease
Treatment
• DDAVP (desmopressin) intranasal or IV
Most Type 1 respond, some Type 2, no Type 3
Contraindicated in Type 2B
• Factor VIII concentrates which include VWFmay be needed in some cases
Inherited Defects ofCoagulation Factors
CAPA 2015 Annual Conference
13
Coagulation Testing (oversimplified)aPTT XII
XI
IX PTVIII VII
X
V
Prothrombin
↓
Thrombin
↓
Fibrinogen Fibrin
Clot
XIII (not tested by PT/PTT)
Thromboelastograph (TEG)
PT & PTTmeasures clotinitiation
90% of clotdynamics occurafter clotinitiation
Coagulation Testing (oversimplified)
XII
XI
IX
VIII VII
X
V
Prothrombin
↓Thrombin
↓
Fibrinogen Fibrin
clot
PT
aPTT
Normal PT withabnormal PTTisolates the problemto these four factors
CAPA 2015 Annual Conference
14
Queen Victoria
Hemophilias
“Classic” hemophilia A
Factor VIII deficiency
Hemophilia B
Factor IX deficiency
“Christmas disease”
CAPA 2015 Annual Conference
15
Hemophilia Severity
Circulating FVIII or FIX level
Normal = 50 –150%
• Severe < 1 %
• Moderate 1 - 5 %
• Mild 6 - 50 %
CAPA 2015 Annual Conference
16
CAPA 2015 Annual Conference
17
CAPA 2015 Annual Conference
18
CAPA 2015 Annual Conference
19
Hemophilia Treatment
• Prevent bleeding !
• Consider prophylactic FVIII or IX (2-3 x wk)
• Treat bleeding early - replace the missingfactor VIII or IX (given IV)
• Monitor for complications such as orthopedic,viral and inhibitors
CAPA 2015 Annual Conference
20
Hemophilia Prophylaxis
• IV Prophylaxisgiven 2 to 3 times aweek can preventmost bleedingepisodes
• Regimen basedmostly on half-life
Hemophilia Treatment
• Donor derived factorconcentrates in the70’s and 80’s led toviral complications
• HBV, HCV, HIV
MMWR
July 16, 1982
Epidemiologic Notesand Reports
Pneumocystis cariniiPneumonia among
Persons withHemophilia A
Hemophilia Treatment
• Safer plasma derived concentrates are now used
• Newer products using recombinant technology
• New products with a longer half-life
• DDAVP used in mild hemophilia A
CAPA 2015 Annual Conference
21
A Recombinant Technology
Mammalian
CELLSproduce aprotein
Protein ispurified
Lyophilized
product
• Mammalian cells are provided with geneticinformation to produce a target protein.
• Cell lines may include CHO, BHK, HEK …
Hemophilia Inhibitors
• Antibodies “inhibitors” develop in ~ 20%of persons with severe hemophilia A
• Antibodies neutralize the infusedcoagulation factor
• May require an “activated” concentrate tocontrol bleeding
Coagulation Testing (oversimplified)
XII
XI
IX
VIII VII
X
V
Prothrombin
↓Thrombin
↓
Fibrinogen Fibrin
clot
PT
aPTT
Normal PTT withabnormal PTisolates the problemto factor VII
CAPA 2015 Annual Conference
22
Coag Factor Deficiencies
Factor VII deficiency
• Autosomal
• Rare 1:500,000
• Bleeding variable
• Bleeding does notcorrelate with level
• Treat with rFVIIa
Factor XI deficiency
• Autosomal
• Rare > 1:100,000
• Ashkenazi Jews (8%)
• Bleeding variable
• Treat with FFP or rVIIa
(No FXI available)
Factor Deficiencies
Factor XII deficiency
• Autosomal
• Rare
• Prolongs the PTT
but does not result in
clinical bleeding
Surgery is OK
Factor XIII deficiency
• Autosomal
• Rare
• PT / PTT normal
• Excess bleeding fromumbilical stump
Federal Regional Hemostasis &Thrombosis Centers (HTCs)
(Hemophilia Treatment Centers)
CAPA 2015 Annual Conference
23
Captain Morgan, The Rescue Dog